caa a22 4500 445356804 CHVBK 20180317142902.0 cr unu---uuuuu 170323e20111101xx s 000 0 eng 10.1007/s10072-011-0799-6 doi (NATIONALLICENCE)springer-10.1007/s10072-011-0799-6 Bevacizumab at recurrence in high-grade glioma [Elektronische Daten] [Andrea Salmaggi, Paola Gaviani, Andrea Botturi, Elena Lamperti, Giorgia Simonetti, Daniela Ferrari, Antonio Silvani] Bevacizumab has been introduced in the management of high-grade gliomas after preliminary studies that showed an acceptable safety and a marked increase in clinico-radiological responses in comparison with second-line chemotherapy. The objective is to synthetically review the present use of bevacizumab—alone or in combination—in the context of recurrent high-grade glioma and highlight the future developments. The methodology of this study is to analyse and discuss relevant literature studies using bevacizumab in recurrent high-grade glioma. Bevacizumab may be used as single-agent therapy in recurrent high-grade glioma, with good clinico-radiological responses having little effect on survival. The open questions and developments include new MRI criteria for evaluation of response to anti-angiogenic agents, the identification of putative factors predicting response/failure of bevacizumab and the introduction of bevacizumab in first-line management of high-grade glioma. Springer-Verlag, 2011 Recurrence nationallicence High-grade glioma nationallicence Bevacizumab nationallicence Salmaggi Andrea Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria, 11, 20133, Milan, Italy aut Gaviani Paola Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria, 11, 20133, Milan, Italy aut Botturi Andrea Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria, 11, 20133, Milan, Italy aut Lamperti Elena Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria, 11, 20133, Milan, Italy aut Simonetti Giorgia Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria, 11, 20133, Milan, Italy aut Ferrari Daniela Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria, 11, 20133, Milan, Italy aut Silvani Antonio Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria, 11, 20133, Milan, Italy aut Neurological Sciences Springer Milan 32(2011-11-01), 251-253 1590-1874 32<251 2011 32 10072 https://doi.org/10.1007/s10072-011-0799-6 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s10072-011-0799-6 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Salmaggi Andrea Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria, 11, 20133, Milan, Italy aut NATIONALLICENCE 700 1- Gaviani Paola Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria, 11, 20133, Milan, Italy aut NATIONALLICENCE 700 1- Botturi Andrea Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria, 11, 20133, Milan, Italy aut NATIONALLICENCE 700 1- Lamperti Elena Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria, 11, 20133, Milan, Italy aut NATIONALLICENCE 700 1- Simonetti Giorgia Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria, 11, 20133, Milan, Italy aut NATIONALLICENCE 700 1- Ferrari Daniela Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria, 11, 20133, Milan, Italy aut NATIONALLICENCE 700 1- Silvani Antonio Neuro-Oncology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Via Celoria, 11, 20133, Milan, Italy aut NATIONALLICENCE 773 0- Neurological Sciences Springer Milan 32(2011-11-01), 251-253 1590-1874 32<251 2011 32 10072 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer